NASDAQ:AFMD
Affimed N.V. Stock News
$5.35
+0.350 (+7.00%)
At Close: Apr 23, 2024
Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares
06:15am, Wednesday, 13'th Jan 2021
Heidelberg, Germany, January 13, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate abil
Affimed Announces Proposed Public Offering of Common Shares
04:01pm, Tuesday, 12'th Jan 2021
Heidelberg, Germany, January 12, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate abil
Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference
06:45am, Monday, 11'th Jan 2021
Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced
Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank
06:30am, Monday, 11'th Jan 2021
Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced
Affimed's Stockpile Of Partnerships Supports A Long-Term Investment
08:40am, Saturday, 19'th Dec 2020
Affimed continues to amass a stockpile of partnerships and collaborations that amplifies the risk-reward profile for an AFMD investment. As a result, I am looking to accumulate a larger position. I pr
Heidelberg, Germany, December 7, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced
Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2020 Results - Earnings Call Transcript
02:46pm, Tuesday, 10'th Nov 2020
Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2020 Results - Earnings Call Transcript
Affimed N.V.'s (AFMD) CEO Adi Hoess On Q3 2020 Results - Quick Version Earnings Call Transcript
10:20am, Tuesday, 10'th Nov 2020
Affimed N.V.'s (AFMD) CEO Adi Hoess On Q3 2020 Results - Quick Version Earnings Call Transcript
Affimed: Q3 Earnings Insights
07:35am, Tuesday, 10'th Nov 2020
Shares of Affimed (NASDAQ:AFMD) rose 11.3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which beat
Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress
06:30am, Tuesday, 10'th Nov 2020
Heidelberg, Germany, Novembe r 10 , 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reporte
Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies
04:01pm, Thursday, 05'th Nov 2020Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition
04:05pm, Wednesday, 04'th Nov 2020
Heidelberg, Germany, November 4, 2020 – Affimed N.V., (NASDAQ: AFMD) a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announced toda
